The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
Can be fatal (PMID 29912044)
Publications
Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report.
The American journal of cardiology 2023 Sep 16;207;35-38 — 2023 Sep 16 — 35-38
Mascolo A, Scavone C, Ferrajolo C, Rafaniello C, Danesi R, Del Re M, Russo A, Coscioni E, Rossi F, Alfano R, Capuano A
Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance.
Drug safety 2021 Jun 18;; — 2021 Jun 18
Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.
The Canadian journal of cardiology 2018 08;34;1059-1068 — 2018 08 — 1059-1068
Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, Monestier S, Grob JJ, Scemama U, Jacquier A, Lalevee N, Barraud J, Peyrol M, Laine M, Bonello L, Paganelli F, Cohen A, Barlesi F, Ederhy S, Thuny F
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Circulation 2017 11 21;136;2085-2087 — 2017 11 21 — 2085-2087